Low-dose rapamycin boosts brain blood flow in people at genetic risk for Alzheimer's

Alzheimer's disease begins in the brain years, even decades, before memory loss appears. One of the earliest changes in people who carry the APOE4 gene variant is reduced blood flow in certain brain regions. A new University of Missouri study suggests that an existing drug, rapamycin, may be able to improve that circulation before symptoms begin.

Rapamycin is approved to prevent organ transplant rejection and to treat certain rare conditions. It inhibits mTOR, a pathway central to aging biology, and has been studied as a way to slow biological aging. Lead researcher Ai-Ling Lin had previously shown in APOE4 mice that rapamycin slowed brain aging and increased blood flow. That raised the question of whether the same would hold in people.

To test this, her team gave a low daily dose of rapamycin for four weeks to healthy adults aged 45 to 65. Some carried APOE4 and some did not. Brain blood flow improved in the APOE4 carriers, but not in the non-carriers. Women showed the strongest benefits. The pattern suggests the drug may be most useful in people whose brain circulation is already vulnerable because of their genetics.

The findings matter because blood flow changes may serve as an early marker of Alzheimer's risk and as a target for intervention. If aging in the brain can be slowed in the highest-risk people, the chance of developing dementia might be reduced. The result adds support for rapamycin as a candidate for prevention-focused trials.

The results should be read with caution. The study was short, used a low dose, and measured blood flow rather than memory, cognition, or dementia. It is not evidence that rapamycin prevents Alzheimer's, and the article does not describe sample size, side effects, or long-term safety. Rapamycin suppresses the immune system at higher doses, so it should not be self-prescribed. Larger, longer, placebo-controlled trials with cognitive outcomes are needed.